Guggenheim initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating for Compass Therapeutics Driven by Promising Tovecimig Results and Strategic Pipeline
- Two new option listings on February 11th
- Optimistic Buy Rating for Compass Therapeutics Due to Promising CTX-009 Trial Results and Market Potential
- Compass Therapeutics price target raised to $8 from $7 at Jefferies